Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1995 1
1998 1
1999 1
2000 1
2001 1
2002 1
2003 1
2005 1
2006 1
2007 3
2008 1
2009 1
2010 3
2011 2
2012 1
2013 1
2014 2
2015 1
2016 1
2017 2
2018 1
2020 2
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

30 results
Results by year
Filters applied: . Clear all
Page 1
Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer.
Scribner JA, Brown JG, Son T, Chiechi M, Li P, Sharma S, Li H, De Costa A, Li Y, Chen Y, Easton A, Yee-Toy NC, Chen FZ, Gorlatov S, Barat B, Huang L, Wolff CR, Hooley J, Hotaling TE, Gaynutdinov T, Ciccarone V, Tamura J, Koenig S, Moore PA, Bonvini E, Loo D. Scribner JA, et al. Among authors: gorlatov s. Mol Cancer Ther. 2020 Sep 23:molcanther.0116.2020. doi: 10.1158/1535-7163.MCT-20-0116. Online ahead of print. Mol Cancer Ther. 2020. PMID: 32967924 Free article.
Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity.
Loo D, Alderson RF, Chen FZ, Huang L, Zhang W, Gorlatov S, Burke S, Ciccarone V, Li H, Yang Y, Son T, Chen Y, Easton AN, Li JC, Rillema JR, Licea M, Fieger C, Liang TW, Mather JP, Koenig S, Stewart SJ, Johnson S, Bonvini E, Moore PA. Loo D, et al. Among authors: gorlatov s. Clin Cancer Res. 2012 Jul 15;18(14):3834-45. doi: 10.1158/1078-0432.CCR-12-0715. Epub 2012 May 21. Clin Cancer Res. 2012. PMID: 22615450 Free article.
Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties.
Nordstrom JL, Gorlatov S, Zhang W, Yang Y, Huang L, Burke S, Li H, Ciccarone V, Zhang T, Stavenhagen J, Koenig S, Stewart SJ, Moore PA, Johnson S, Bonvini E. Nordstrom JL, et al. Among authors: gorlatov s. Breast Cancer Res. 2011;13(6):R123. doi: 10.1186/bcr3069. Epub 2011 Nov 30. Breast Cancer Res. 2011. PMID: 22129105 Free PMC article.
FcγRIIb-BCR coligation inhibits BCR signaling in chronic lymphocytic leukemia.
Bosch R, Mora A, Cuellar C, Ferrer G, Gorlatov S, Nomdedéu J, Montserrat E, Sierra J, Rai KR, Chiorazzi N, Moreno C. Bosch R, et al. Among authors: gorlatov s. Haematologica. 2021 Jan 1;106(1):306-309. doi: 10.3324/haematol.2019.245795. Haematologica. 2021. PMID: 32336680 Free PMC article. No abstract available.
FcγRIIb expression in early stage chronic lymphocytic leukemia.
Bosch R, Mora A, Vicente EP, Ferrer G, Jansà S, Damle R, Gorlatov S, Rai K, Montserrat E, Nomdedeu J, Pratcorona M, Blanco L, Saavedra S, Garrido A, Esquirol A, Garcia I, Granell M, Martino R, Delgado J, Sierra J, Chiorazzi N, Moreno C. Bosch R, et al. Among authors: gorlatov s. Leuk Lymphoma. 2017 Nov;58(11):2642-2648. doi: 10.1080/10428194.2017.1307981. Epub 2017 Apr 4. Leuk Lymphoma. 2017. PMID: 28372509 Free PMC article.
Development of MGD007, a gpA33 x CD3-Bispecific DART Protein for T-Cell Immunotherapy of Metastatic Colorectal Cancer.
Moore PA, Shah K, Yang Y, Alderson R, Roberts P, Long V, Liu D, Li JC, Burke S, Ciccarone V, Li H, Fieger CB, Hooley J, Easton A, Licea M, Gorlatov S, King KL, Young P, Adami A, Loo D, Chichili GR, Liu L, Smith DH, Brown JG, Chen FZ, Koenig S, Mather J, Bonvini E, Johnson S. Moore PA, et al. Among authors: gorlatov s. Mol Cancer Ther. 2018 Aug;17(8):1761-1772. doi: 10.1158/1535-7163.MCT-17-1086. Epub 2018 Jun 4. Mol Cancer Ther. 2018. PMID: 29866746 Free article.
Enhancing the potency of therapeutic monoclonal antibodies via Fc optimization.
Stavenhagen JB, Gorlatov S, Tuaillon N, Rankin CT, Li H, Burke S, Huang L, Johnson S, Koenig S, Bonvini E. Stavenhagen JB, et al. Among authors: gorlatov s. Adv Enzyme Regul. 2008;48:152-64. doi: 10.1016/j.advenzreg.2007.11.011. Epub 2007 Dec 3. Adv Enzyme Regul. 2008. PMID: 18177741 No abstract available.
30 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page